Can the 'Love Hormone' help schizophrenia patients connect better?
NCT ID NCT06136390
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether giving oxytocin nasal spray before mindfulness-based group therapy could reduce negative symptoms (like lack of motivation or social withdrawal) in people with schizophrenia. 42 participants were randomly assigned to receive either oxytocin or a placebo spray before each therapy session. The goal was to see if oxytocin, which plays a role in social bonding, could enhance the benefits of group therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Oxytocin nasal spray
What this could lead to
If it works, this could point toward a way to improve social function and reduce negative symptoms in schizophrenia.
What could go wrong
This is a small, early-stage trial with only 42 participants. Previous results with oxytocin in schizophrenia have been inconsistent, so the added benefit may be modest or absent.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA SPECTRUM DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
Berlin, State of Berlin, 12203, Germany